Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine

European Journal of Internal Medicine

Volumn 15, Issue 4, 2004, Pages 255-258

  Claes, Petra ^a   Wintzen, Marjolein ^b   Allard, Sabine ^a   Simons, Patrick ^a   De Coninck, Arlette ^a   Lacor, Patrick ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cutaneous adverse reaction; HIV; Immunoglobulin; N acetylcysteine; Nevirapine; TEN; Toxic hepatitis

Indexed keywords

ABACAVIR; ACETYLCYSTEINE; ACICLOVIR; ANTIINFECTIVE AGENT; ANTIPYRETIC AGENT; ANTIRETROVIRUS AGENT; CLINDAMYCIN; DIDANOSINE; FLUCONAZOLE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IVEGAM; LAMIVUDINE; NEVIRAPINE; PARACETAMOL; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; CONJUNCTIVITIS; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHYSICAL EXAMINATION; PRURITUS; RASH; SIDE EFFECT; SKIN NECROSIS; STEVENS JOHNSON SYNDROME; STOMATITIS; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS;

EID: 3543098127     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2004.04.007     Document Type: Article

References (23)

1. Fagot J.P., Mockenhaupt M., Bouwes-Bavinck J.N., Naldi L., Viboud C., Roujeau J.C. EuroSCAR Study Group Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 15(14):2001;1843-1848
2. Brambilla G., Brucato F., Angrisano A., Palmieri G. Treatment of toxic epidermal necrolysis (TEN). Ann. Burns Fire disasters. 15(1):2002 (March);17-21
3. Vélez A., Moreno J.C. Toxic epidermal necrolysis treated with N-acetylcysteine. Letter. J. Am. Acad. Dermatol. 46(3):2002 (March);469-470
4. Becker D.S. Toxic epidermal necrolysis. Seminar. Lancet. 351(9113):1998 (March);1417-1420
5. Petersen, KM. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatric Pharmacotherapy. A Monthly Review for Health Care Professionals of the Children's Medical Center; 1998 Nov. 4 (11).
6. Rotunda A., Hirsch R.J., Scheinfeld N., Weinberg J.M. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm. Venereol. 83(1):2003;1-9
7. Wolkenstein P., Carriere V., Charue D., et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics. 5:1995;255-258
8. Bonnet F., Lawson-Ayayi S., Thiebaut R., et al. French Aquitaine Cohort. Groupe d' Epidémiologie Clinique du SIDA en Aquitaine (GESCA). A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort 1997-1999. Clin. Infect. Dis. 35(10):2002 (Nov. 15);1231-1237
9. Boehringer Ingelheim International Guidelines Boehringer Ingelheim International spring symposium 2003, Cannes France:2003
10. Warren K.J., Boxwell D.E., Kim N.Y., Drolet B.A. (Letter) Nevirapine-associated Stevens-Johnson syndrome. Lancet. 351:1998;567
11. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. 20(6):1998 (Nov.-Dec.);1071-1092
12. Ghislain P.D., Roujeau J.C. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Review. Dermatol. Online J. 8(1):2002 (Jun.);5
13. Paquet P., Piérard G.E. Would cyclosporinA be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology. 1999;198-202
14. Egan C.A., Grant W.J., Morris S.E., Saffle J.R., Zone J.J. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J. Am. Acad. Dermatol. 40:1999;458-461
15. Paquet P., Jacob E., Damas P., Piérard G.E. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns. 27(6):2001;625-655
16. Roujeau J.C. Treatment of severe drug eruptions. Review. J. Dermatol. 26(11):1999 (Nov.);718-722
17. Prins C., Kerdel F.A., Padilla R.S., et al. for the TEN-IVIG Study Group Multicenter retrospective analysis of 48 consecutive cases. Arch. Dermatol. 139(1):2003 (Jan.);26-32
18. Redondo P., De Felipe I., De la Peña A., Aramendia J.M., Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with N-acetylcysteine. Br. J. Dermatol. 136:1997;645-646
19. Kelly G.S. Clinical applications of N-acetylcysteine. Review. Altern. Med. Rev. 3(2):1998 (Apr.);114-127
20. DeRosa S.C., Zaretsky M.D., Dubs J.G., et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Invest. 30(10):2000 (Oct.);915-929
21. Mackie N.E., Fidler S., Tamm N., Clarke J.R., Weber J.N., Taylor G.P. Clinical implications of stopping nevirapine-based antiretroviral theraphy: relative pharmacokinetics and avoidance of drug resistance. HIV Medicine. 5(3):2004 (May);180-184
22. Riska P., Lamson M., MacGregor T., Sabo J., Hattox S., Pav J., et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 27(8):1999 (Aug.);895-901
23. Claes P., Wintzen M., Allard S., Simons P., De Coninck A., Lacor P. An HIV-infected patient with nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcystein. Accepted as a poster at the conference of the European Federation of Internal Medicine, September 2003, Berlin:2003